Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H31ClFN5O4S |
| Molecular Weight | 564.072 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)[C@H](NC(=O)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3Cl)C(=O)NCCNS(=O)(=O)C4CC4
InChI
InChIKey=UANJTRHQSBHCID-HSZRJFAPSA-N
InChI=1S/C26H31ClFN5O4S/c1-26(2,3)23(25(35)29-13-14-30-38(36,37)18-11-12-18)31-24(34)21-19-5-4-6-20(27)22(19)33(32-21)15-16-7-9-17(28)10-8-16/h4-10,18,23,30H,11-15H2,1-3H3,(H,29,35)(H,31,34)/t23-/m1/s1
| Molecular Formula | C26H31ClFN5O4S |
| Molecular Weight | 564.072 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:18:25 GMT 2023
by
admin
on
Sat Dec 16 10:18:25 GMT 2023
|
| Record UNII |
L6K9PBL5EO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-ADSB-FUB-187
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
L6K9PBL5EO
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY | |||
|
DTXSID701032540
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY | |||
|
ADSB-FUB-187
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY | ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values. Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products. | ||
|
44186812
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY | |||
|
ADSB-FUB-187
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY | |||
|
1185283-97-9
Created by
admin on Sat Dec 16 10:18:25 GMT 2023 , Edited by admin on Sat Dec 16 10:18:25 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
